|
Market Closed -
Other stock markets
|
After hours 20:00:00 | |||
| 48.99 USD | -2.08% |
|
66.96 | +36.69% |
| 07-29 | Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says | MT |
| 07-28 | Alkermes plc, Q2 2026 Earnings Call, Jul 28, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKERMES PLC | Other Biotechnology & Medical Research | -2.08% | -7.37% | +75.09% | +84.94% | +89.37% | 8.22B |  |  | |
- Stock Market
- Stocks
- ALKS Stock
- Charts Alkermes plc
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
